Objectif
The balance between cell proliferation and differentiation, which deregulation is central to carcinogenesis, is controlled through the interactions between key proteins. These proteins are sensitive to gain-of-function or loss-of-function mutations in cancer, and thus represent potential targets for cancer therapy. Recent basic advances on cell-fate controlling regulatory pathways have demonstrated a key role for histone acetyl-transferases (HATs) and histone deacetylases (HDs).
The objectives are:
1- to further characterise, at the molecular level, regulatory pathways involving HATs / HDs in normal cells;
2- to analyse HATs / HDs in cancer cells;
3- to demonstrate that restoring normal function of these enzymes in cancer cells, by modifying their interaction with other proteins, reverses the phenotype.
After completion of these steps, drug screening will be set up to reveal new drugs directed against these enzymes.
Champ scientifique
Appel à propositions
Data not availableRégime de financement
CSC - Cost-sharing contractsCoordinateur
94801 VILLEJUIF
France